Analyst Price Targets — PEN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 26, 2026 3:48 pm | Priya Sachdeva | UBS | $374.00 | $340.24 | StreetInsider | UBS Reiterates Neutral Rating on Penumbra (PEN) Following Q4 Results |
| February 25, 2026 7:48 pm | — | Evercore ISI | $360.00 | $338.70 | TheFly | Penumbra price target raised to $360 from $340 at Evercore ISI |
| January 20, 2026 11:34 am | — | RBC Capital | $374.00 | $350.78 | TheFly | Penumbra downgraded to Sector Perform from Outperform at RBC Capital |
| January 20, 2026 10:06 am | — | Canaccord Genuity | $374.00 | $350.78 | TheFly | Penumbra downgraded to Hold from Buy at Canaccord |
| January 16, 2026 1:55 pm | — | Jefferies | $374.00 | $350.98 | TheFly | Penumbra downgraded to Hold from Buy at Jefferies |
| January 16, 2026 7:55 am | David Rescott | Robert W. Baird | $374.00 | $350.49 | StreetInsider | Baird Downgrades Penumbra (PEN) to Neutral |
| January 16, 2026 7:12 am | Mike Kratky | Leerink Partners | $374.00 | $350.49 | StreetInsider | Leerink Partners Downgrades Penumbra (PEN) to Market Perform |
| January 16, 2026 5:46 am | Richard Newitter | Truist Financial | $374.00 | $350.49 | StreetInsider | Truist Securities Downgrades Penumbra (PEN) to Hold |
| January 15, 2026 9:12 pm | Ryan Zimmerman | BTIG | $349.00 | $350.49 | TheFly | Penumbra downgraded to Neutral from Buy at BTIG |
| January 15, 2026 4:38 pm | — | Wells Fargo | $374.00 | $351.27 | TheFly | Penumbra downgraded to Equal Weight from Overweight at Wells Fargo |
Latest News for PEN
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ALAMEDA, Calif., April 13, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) announced 90-day results of the landmark STORM-PE randomized controlled trial (RCT), which found that patients with acute intermediate-high risk pulmonary embolism (PE) who were treated with computer assisted vacuum thrombectomy (CAVT™) plus anticoagulation achieved greater functional improvement, including walking significantly further and a…
Penumbra (PEN) could produce exceptional returns because of its solid growth attributes.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Penumbra, Inc. (NYSE: PEN) to Boston Scientific Corporation (NYSE: BSX). Under the terms of the proposed transaction, shareholders of Penumbra will receive $374.00 in cash or 3.8721 shares of Boston Scientific common stock,…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PEN.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.